Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012278 | 1.00 | ATM (0.35) | ATMHDAC8RENCMA1ITGB3 | |
| SCHEMBL16012027 | 0.93 | ALDH1A1 (0.33) | HDAC8REN | |
| SCHEMBL17364182 | 0.93 | ALDH1A1 (0.33) | HDAC8REN | |
| SCHEMBL13830430 | 0.91 | ATM (0.36) | ATMHDAC8RENCMA1ITGB3 | |
| SCHEMBL16011884 | 0.88 | ATM (0.34) | ATMHDAC8RENCMA1 | |
| SCHEMBL16011885 | 0.88 | ATM (0.34) | ATMHDAC8RENCMA1 | |
| SCHEMBL18827805 | 0.87 | ATM (0.38) | ATMHDAC8CMA1ITGB3ITGA2B | |
| SCHEMBL18557649 | 0.86 | CMA1 (0.43) | RENCMA1ITGB3ITGA2BACE | |
| SCHEMBL15668840 | 0.84 | ATM (0.36) | ATMHDAC8CMA1ACE | |
| SCHEMBL15668693 | 0.84 | ATM (0.36) | ATMHDAC8CMA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580463-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580463-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2964664-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2964664-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2964664-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-31 | — | — | US | disclosed |
| WO-2014137869-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014137869-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | ATM 4436/4885HDAC8 2235/4885REN 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.